Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0851184 (thinning)
 11,252 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Clobetasone butyrate ointment has been shown to be more effective in treating psoriasis and eczema than flurandrenolone ointment yet to cause less epidermal thinning in a human experimental model. This is an indication that the clinical activity of topical glucocorticoids may not necessarily be inseparable from their propensity to cause atrophy of the skin.
 ...
PMID:A separation of clinical from epidermal thinning effect in the topical glucocorticoid clobetasone butyrate. 32 Sep 95

Twenty eight patients with various dermatological conditions were treated orally with the new aromatic derivate of retinoic acid, Ro 10-9359. The initial average dose was 48,3 mg/day and the maintenance dose was 26,6 mg/day. Duration of treatment ranged between 3 to 6 months. Evolution of erythema, infiltration and hyperkeratosis showed changes statistically significant (p < 0,05) and excellent to good results were obtained in 23 out of the 28 treated patients. On the basis of this study it is concluded that Ro 10-9359 is a promising drug for the treatment of several skin diseases, specially ichthyosis, Darier's disease, oral lichen planus, erythrokeratoderma variabilis and psoriasis. No serious side effects were reported; dryness of the lips, scaling of palms and soles, pruritus and thinning of the skin were the most common. In no case treatment was discontinued due to side effects. Laboratory controls did not show deviations from the normal values.
 ...
PMID:[Oral treatment of various dermatosis with the aromatic derivative of retinoic acid Ro 10-9359]. 39 25

Anthracene with near ultraviolet (UV) light (UVA, 320--400 nm) has been shown previously to inhibit epidermal deoxyribonucleic acid (DNA) synthesis and mitosis. This suggested that the combination of anthracene and UVA light could suppress the rapidly proliferating epidermis of psoriasis. In this preliminary clinical study, anthracene plus UVA light improved psoriasis as shown by thinning of plaques and decreased scale in four of five patients, with complete or almost complete clearing in two of these four patients. These findings indicate that anthracene with UVA light might be helpful in the control of psoriasis.
 ...
PMID:Psoriasis improved by anthracene with near ultraviolet light. 51 76

The epidermis of pyogenic granulomata is presented with an unusual problem of distorted dermoepidermal relationships. In this study we have attempted to delineate the problem and have studied the way in which the epidermis copes with its difficulties. Sixteen pyogenic granulomata with (where possible) paralesional skin (and for comparison ten Campbell de Morgan spots) were studied by cell kinetic techniques. High labelling indices were found in the epidermis and in the endothelium in the pyogenic granulomata (contrasting strikingly with the findings in the Campbell de Morgan spots). A variable morphological response was found ranging from hyperplasia with parakeratosis to epidermal thinning and atrophy. Possible mechanisms for the epidermal changes are discussed and it is suggested that the data produced from this and similar studies may aid the understanding of dermo-epidermal interaction in a variety of common skin disorders including psoriasis.
 ...
PMID:Dermo-epidermal relationships in pyogenic granulomata. 70 23

The aromatic retinoic acid derivative Ro 10-9359 was administered orally to 25 severe psoriatic patients (14 with generalized plaques, 7 erythrodermic, 4 pustular). The initial dose was 25 mg/20 kg body weight daily for 4 weeks; afterwards the same posology was given every other day during several months (Max : 18 months). Excellent results were obtained in 16 patients (64 p. 100) particularly in severe erythrodermic and pustular psoriasis. However, under follow-up therapy relapses sometimes occurred leading to temporary resumption of initial posology. The most important side effects are cheilitis, palmoplantar scaling with thinning of the skin, hyperhidrosis and diffuse hair loss. A slight increase of transaminases and of alkaline phosphatases was found in a few patients. The Ro 10-9359 compound is a very useful new therapy of severe psoriasis.
 ...
PMID:[Oral treatment of severe psoriasis with a new aromatic retinoid (Ro 10-9359) (author's transl)]. 74 93

Tigason (etretinate, RO-10-9359) is an oral aromatic retinoid acid which is effective in psoriasis and other dermatological syndromes. The present study reports the results of the use of this drug in 15 patients with a confirmed diagnosis of psoriatic arthritis, aged between 42 and 74 (average 60.2) years. Two patients dropped out after one month because they showed dryness of lips, chapping and intolerable itching, and another two due to intolerable pruritus and deterioration of their skin lesions. The 11 remaining patients, five males and six females, were treated with a daily dose of 50 mg etretinate, reduced to 25 mg after two weeks. Assessments which included grip strength, Ritchie joint index, pain, and dermatological assessment were performed at monthly intervals. Routine blood tests for toxic effects and erythrocyte sedimentation rate (ESR) were also performed, as well as CPR (C-protein reactive) as a test of disease activity. All patients showed an improvement in the psoriasis, joint swelling and pain. The elevated ESR observed in all patients studied also fell gradually during the course of etretinate treatment, as did as the intake of antiinflammatory agents. Elevated serum lipid levels (cholesterol and triglycerides) were found in three patients; further drug-specific side-effects such as dryness of lips and mouth, loss of hair, thinning of skin and scaling were frequently found in all patients, but they remained tolerable.
 ...
PMID:Tigason (etretinate) treatment in psoriatic arthritis. 339 51

Dithranol, 10-propionyl dithranol and 10-butyryl dithranol were compared as regards their antipsoriatic, staining and irritative properties. They were applied under 12-mm Finnchambers on the lesional skin of 17 psoriasis patients every second day for 20 days. In 9 patients their concentration was equimolar (2 mmol/kg of white petrolatum) corresponding to 0.05% dithranol, and in 8 patients the concentrations were 2, 4, and 8 mmol for dithranol, 10-propionyl dithranol and 10-butyryl dithranol, respectively. Without regard to the concentration, they all produced under occlusion almost equal thinning of the lesions, but when a 2 mmol concentration was used, 10-butyryl dithranol (butantrone) showed least staining and irritation on the treated sites.
 ...
PMID:Antipsoriatic activity of 10-acyl analogues of dithranol (anthralin). I. Phase I clinical trial of 10-propionyl dithranol and 10-butyryl dithranol (butantrone). 620 85

Two patients with severe generalized psoriasis and psoriatic arthritis whose conditions had failed to respond to oral therapy with traditional remedies, including etretinate (both patients) and its combination with psoralen and UV-A (PUVA) (one patient) were successfully treated with minimal oral dosages of the arotinoid RO 13-6298 (0.05 to 0.1 mg/day). Side effects of this new synthetic retinoid included dryness of the lips and nasal mucosa, some palmarplantar desquamation, gross thinning of the skin, itching, and transient hair loss. Laboratory investigations disclosed no abnormalities attributable to the drug. The new arotinoid, RO 13-6298, seems to be a highly potent retinoid in its antipsoriatic effects. It represents the third generation of synthetic retinoids that may be effective in extremely low doses.
 ...
PMID:Antipsoriatic activity of a new synthetic retinoid. The arotinoid RO 13-6298. 661 62

Symmetric lesions of ten psoriasis patients were treated with anthralin and a combination of anthralin and steroid to compare the effect of these two therapies. After treatment, tissue was excised from the papules. An in vitro double-labeling autoradiography with 3H- and 14C-thymidine was then carried out. The thickness of the epidermis was also measured. The anthralin therapy leads to significantly greater inhibition of proliferation than the combined therapy with steroid. On the other hand, the combined therapy significantly shortens the duration of the S-phase, which is pathologically lengthened in psoriasis patients. The combined therapy also leads to significantly greater thinning of the epidermis.
 ...
PMID:[Effect of the treatment of psoriasis with dithranol in comparison with a combination of dithranol and a corticosteroid]. 664 55

Origin of epidermal urea and the therapeutical possibilities are shown: the waterbinding, keratolytic, epidermal thinning, antipruriginous, and the penetrating-supporting effects. Our clinical studies revealed mild to moderate eczemas and psoriasis capitis to be treated with a 10% urea-, 1% hydrocortisone cream. A 10% urea cream is well indicated for mild palmar and plantar hyperkeratotic dermatitis, the after treatment of contact dermatitis, and senile atrophic skin. Serious hyperkeratotic palmar dermatitis gives better results when handled alternately with triamcinolone-acetonid cream and a 10% urea cream.
 ...
PMID:[Urea and its therapeutic possibilities]. 685 12


1 2 3 4 5 Next >>